Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

idahoranch1

ladyPI

summer_sky

To: erickerickson who wrote (38484)	1/7/2017 12:18:28 AM
From: allatwwk	3 Recommendations of 63293

Erick -- my main issue with IMMU mgmt is simple enough. They never figured out what they were genuinely good at and genuinely bad at. This biz should have been partnering up every molecule they could at the earliest possible stage. This would have let them do what they do best, which is run a development lab and develop new drugs. Instead, they spent money, time and energy taking trials far further than they should have gone on their own dime. They failed to acquire expertise in partnering, which is the one critical complement needed for a lab oriented business. They wanted to control all the marbles, and its been a terrible approach to running the business, especially one with very limited cash. Couple this with ill-timed financings and here we are.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next